Weekly Paclitaxel + Bevacizumab (platinum-resistant recurrent ovarian, AURELIA)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PACLITAXEL` `DRUG-BEVACIZUMAB`

ID	`REG-WEEKLY-PAC-BEV-OVARIAN`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-AURELIA-PUJADE-LAURAINE-2014` `SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Notes

AURELIA weekly-paclitaxel arm: mPFS 10.4 vs 3.9 mo (HR 0.46); ORR 53.3% vs 30.2%. OS subgroup analysis: 22.4 vs 13.2 mo (HR 0.65) — only AURELIA chemo arm with statistically significant OS benefit. Preferred AURELIA backbone when no contraindication to paclitaxel re-exposure (no significant residual neuropathy).

Used By

Indication

IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB - IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB
IND-OVARIAN-2L-PLAT-RES-PLD-BEV - IND-OVARIAN-2L-PLAT-RES-PLD-BEV
IND-OVARIAN-2L-PLAT-RES-WEEKLY-PAC-BEV - IND-OVARIAN-2L-PLAT-RES-WEEKLY-PAC-BEV

Regimen

REG-PLD-BEV-OVARIAN - PLD + Bevacizumab (platinum-resistant recurrent ovarian, AURELIA)